For instance, in HER2 IHC – a common and highly relevant test to determine eligibility for anti‐HER2 therapy in breast cancer patients – control tumour tissues with established HER2 statuses are included on the same slide as the patient sample [4]. Here, ERBB2 is linked to breast carcinoma.